Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g. NEAR(recruit, professionals, 20)).
Finds documents with the search term in word versions or composites. The asterisk * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g. lightweight*, *lightweight, *lightweight*).
Improved survival in pediatric oncology has highlighted the growing burden of cancer treatment-related cardiotoxicity. Delve into the recent advances and emerging priorities in this setting.
Explore current insights into microbiota–immune interactions in pancreatic cancer, microbiome-targeted therapeutic strategies, and promising approaches to enhance immunotherapy outcomes.
Among people with cancer, the presence of fatigue before starting treatment is associated with an increased risk for severe, life-threatening, or fatal adverse events.
Colonic leiomyosarcoma is a rare and aggressive tumor that is often difficult to diagnose preoperatively, especially in a case such as this where multiple biopsies were inconclusive.
Research suggests this is achievable in selected cases through trigger removal, immune reset, or profound immune depletion. But advancing this paradigm requires standardized definitions, predictive biomarkers, and long-term trials.
Catch up on all the latest news, guidance and expert opinion from the 2025 ASH annual meeting, including updates in sickle cell disease, multiple myeloma, lymphoma, transplants.
Are you up to date on targeted therapies for relapsed/refractory AML?
Join Prof. Amer Zeidan and his expert guests to hear about innovations in molecular testing, emerging therapies, and IDH-targeted treatments, and get practical advice for improving your patient care.
Supported by: independent educational grant from Rigel
Join Professor Joy Ho as she leads a panel of Asia-Pacific-based experts, discussing real-life patient cases and their experiences with CAR T-cell therapy for the treatment of R/R DLBCL or R/R FL. Learn about how to identify appropriate patients for CAR T-cell therapy and how to optimize outcomes with this treatment modality. Gain insights into essential aspects of pre- and post-infusion management, as well as important considerations for treatment sequencing.
This educational activity is not intended for healthcare professionals based in the UK, US, or off-label Asia-Pacific countries.
Colonic leiomyosarcoma is a rare and aggressive tumor that is often difficult to diagnose preoperatively, especially in a case such as this where multiple biopsies were inconclusive.
A case illustrating a rare but important association between Behçet disease and Hodgkin lymphoma, possibly mediated by immune dysregulation and chronic immunosuppression.
A 32-year-old woman presented with overlapping anti-NMDA-R and anti-GFAP encephalitis refractory to immunotherapy due to an occult neoplasm, emphasizing the importance of searching for underlying tumors in treatment-resistant cases.
CRC remains a major global health burden, but advances in screening, treatment, and lifestyle-based prevention continue to reshape clinical practice. Gain insights into how the latest research can be leveraged to optimize patient care across the CRC continuum.
Chemotherapy-induced nausea and vomiting (CINV) remains one of the most distressing adverse effects of antineoplastic therapy despite major advances in antiemetic management. The introduction of serotonin (5-HT3) and neurokinin‑1 (NK1) receptor …
The advent of comprehensive genomic profiling has revolutionized not only the identification of the tissue of origin in cancer of unknown primary (CUP) but also enabled the detection of potentially actionable molecular alterations. Recent evidence …
The Danish National Patient Registry (DNPR) and the Danish Cancer Registry (DCR) are central to registry-based cancer research. This systematic review evaluates studies assessing the quality of cancer-related data in these registries under their …
Observational studies have linked maternal hormonal contraception use to childhood cancer risk, but findings are inconsistent. A systematic review was conducted of this potential relationship. A systematic search was performed in PubMed, Embase …
Marking a major milestone in chronic myeloid leukemia treatment
Tyrosine kinase inhibitors have transformed the treatment of chronic myeloid leukemia, a condition that had limited therapeutic options before.
In this 25th year since the first phase 2 trials of the first TKI, we speak to a researcher and clinician who has been involved since the early days. Dr. Jorge Cortes shares his experience and talks about the impact of these drugs, not only in the treatment of CML but also more widely.
Professor Joy Ho and a panel of Asia-Pacific-based experts will examine real-life patient cases in this Masterclass, exchanging insights into their clinical experiences of using CAR T-cell therapy to treat patients with R/R DLBCL or R/R FL.
This educational activity is not intended for healthcare professionals based in the UK, US, or off-label Asia-Pacific countries.
This hub presents a curated selection of educational materials focused on the latest clinically relevant topics related to the use of chimeric antigen receptor (CAR) T‑cell therapy for the treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and R/R follicular lymphoma (FL).
This content has been developed in collaboration with and funded by the sponsor Novartis Pharma AG and is not intended for healthcare professionals based in the UK and US.
Hear directly from experts in acute myeloid leukemia about innovations in molecular testing, emerging therapies, and targeted treatments, and get practical advice for improving the care of your patients with relapsed or refractory disease.
Chemotherapy-induced nausea and vomiting (CINV) remains one of the most distressing adverse effects of antineoplastic therapy despite major advances in antiemetic management. The introduction of serotonin (5-HT3) and neurokinin‑1 (NK1) receptor …
The advent of comprehensive genomic profiling has revolutionized not only the identification of the tissue of origin in cancer of unknown primary (CUP) but also enabled the detection of potentially actionable molecular alterations. Recent evidence …
Among people with cancer, the presence of fatigue before starting treatment is associated with an increased risk for severe, life-threatening, or fatal adverse events.
Improved survival in pediatric oncology has highlighted the growing burden of cancer treatment-related cardiotoxicity. Delve into the recent advances and emerging priorities in this setting.